TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Analyst Earnings Estimates
NYSE:TAK - New York Stock Exchange, Inc. - US8740602052 - ADR - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 3.569T 11.61% | 4.027T 12.85% | 4.264T 5.87% | 4.535T 6.36% | 4.56T 0.55% | 4.639T 1.74% | |
| EBITDA YoY % growth | 1.129T 26.05% | 1.215T 7.68% | 1.159T -4.65% | 1.187T 2.46% | 1.219T 2.67% | 1.268T 3.99% | |
| EBIT YoY % growth | 545.488B 62.48% | 550.895B 0.99% | 430.787B -21.80% | 228.26B -47.01% | 401.98B 76.11% | 503.99B 25.38% | |
| Operating Margin | 15.28% | 13.68% | 10.10% | 5.03% | 8.82% | 10.86% | |
| EPS YoY % growth | 73.59 -38.72% | 102.15 38.81% | 46.02 -54.95% | 41.02 -10.86% | 64.35 56.86% | 80.21 24.65% |
All data in JPY
| Q4 / 25 | Q1 / 26 | |
|---|---|---|
| EPS Q2Q % growth | -21.19 -2,009.90% | 25.34 -16.48% |
| Revenue Q2Q % growth | 1.063T 1.20% | 1.138T -5.81% |
| EBITDA Q2Q % growth | -5.584B -100.73% | N/A |
| EBIT Q2Q % growth | N/A | N/A |
All data in JPY
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | 7.43 -78.01% | 12.71 | -5.29 | -41.58% |
| Q2 2025 Q2Q % growth | 29.05 287.55% | 16.55 | 12.50 | 75.50% |
| Q1 2025 Q2Q % growth | 30.34 5.56% | 22.09 | 8.25 | 37.34% |
| Q4 2024 Q2Q % growth | -1.00 -110.03% | 0.39 | -1.39 | -357.78% |
| Q3 2024 Q2Q % growth | 33.78 -11.88% | 14.38 | 19.39 | 134.84% |
| Q2 2024 Q2Q % growth | -15.49 -177.99% | 18.39 | -33.88 | -184.23% |
| Q1 2024 Q2Q % growth | 28.74 -15.35% | 34.91 | -6.18 | -17.69% |
| Q4 2023 Q2Q % growth | 10.01 388.22% | 6.78 | 3.23 | 47.57% |
| Q3 2023 Q2Q % growth | 38.33 107.24% | 37.62 | 0.71 | 1.89% |
| Q2 2023 Q2Q % growth | 19.86 35.93% | 19.30 | 0.56 | 2.91% |
| Q1 2023 Q2Q % growth | 33.95 -22.76% | 35.90 | -1.95 | -5.43% |
| Q4 2022 Q2Q % growth | -3.47 -105.51% | 3.01 | -6.48 | -215.36% |
| Q3 2022 Q2Q % growth | 18.49 -37.36% | 25.52 | -7.03 | -27.54% |
| Q2 2022 Q2Q % growth | 14.61 1,229.27% | 23.87 | -9.26 | -38.79% |
| Q1 2022 Q2Q % growth | 43.96 66.19% | 33.97 | 9.99 | 29.40% |
| Q4 2021 Q2Q % growth | 63.01 11,362.22% | 24.19 | 38.82 | 160.51% |
| Q3 2021 Q2Q % growth | 29.53 886.43% | 21.90 | 7.63 | 34.83% |
| Q2 2021 Q2Q % growth | 1.10 -93.64% | 16.43 | -15.33 | -93.31% |
| Q1 2021 Q2Q % growth | 26.45 498.57% | 8.10 | 18.35 | 226.72% |
| Q4 2020 Q2Q % growth | 0.55 101.14% | -53.07 | 53.62 | 101.04% |
| Q3 2020 Q2Q % growth | 2.99 -87.64% | -15.27 | 18.27 | 119.60% |
| Q2 2020 Q2Q % growth | 17.29 -43.93% | -23.52 | 40.81 | 173.52% |
| Q1 2020 Q2Q % growth | -6.64 -113.27% | -21.95 | 15.32 | 69.77% |
| Q4 2019 Q2Q % growth | -48.16 | -40.19 | -7.96 | -19.81% |
| Q2 2019 Q2Q % growth | 30.84 | 18.97 | 11.86 | 62.53% |
| Q1 2019 Q2Q % growth | 50.00 | 34.97 | 15.03 | 42.98% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | 1.144T 2.96% | 1.15T | -5.501B | -0.48% |
| Q2 2025 Q2Q % growth | 1.176T 12.75% | 1.106T | 70.201B | 6.35% |
| Q1 2025 Q2Q % growth | 1.208T 14.11% | 1.104T | 104.296B | 9.45% |
| Q4 2024 Q2Q % growth | 1.051T 9.91% | 916.958B | 133.911B | 14.60% |
| Q3 2024 Q2Q % growth | 1.111T 1.33% | 1.017T | 93.961B | 9.24% |
| Q2 2024 Q2Q % growth | 1.043T 4.07% | 1.009T | 33.671B | 3.34% |
| Q1 2024 Q2Q % growth | 1.059T 8.86% | 992.223B | 66.395B | 6.69% |
| Q4 2023 Q2Q % growth | 956.156B 9.49% | 966.415B | -10.259B | -1.06% |
| Q3 2023 Q2Q % growth | 1.097T 21.66% | 1.015T | 81.727B | 8.05% |
| Q2 2023 Q2Q % growth | 1.002T 18.64% | 962.035B | 40.272B | 4.19% |
| Q1 2023 Q2Q % growth | 972.465B 2.41% | 934.47B | 37.995B | 4.07% |
| Q4 2022 Q2Q % growth | 873.289B 13.37% | 847.458B | 25.831B | 3.05% |
| Q3 2022 Q2Q % growth | 901.294B 7.71% | 846.517B | 54.777B | 6.47% |
| Q2 2022 Q2Q % growth | 844.82B 7.08% | 825.266B | 19.554B | 2.37% |
| Q1 2022 Q2Q % growth | 949.603B 18.43% | 873.46B | 76.143B | 8.72% |
| Q4 2021 Q2Q % growth | 770.274B -0.19% | 791.881B | -21.607B | -2.73% |
| Q3 2021 Q2Q % growth | 836.753B -2.63% | 847.525B | -10.772B | -1.27% |
| Q2 2021 Q2Q % growth | 788.935B -2.73% | 840.261B | -51.326B | -6.11% |
| Q1 2021 Q2Q % growth | 801.85B -5.57% | 814.274B | -12.424B | -1.53% |
| Q4 2020 Q2Q % growth | 771.702B 7.60% | 802.131B | -30.429B | -3.79% |
| Q3 2020 Q2Q % growth | 859.317B 72.07% | 844.174B | 15.143B | 1.79% |
| Q2 2020 Q2Q % growth | 811.048B 88.28% | 822.735B | -11.687B | -1.42% |
| Q1 2020 Q2Q % growth | 849.121B 88.76% | 824.716B | 24.405B | 2.96% |
| Q4 2019 Q2Q % growth | 717.211B | 761.028B | -43.817B | -5.76% |
| Q2 2019 Q2Q % growth | 430.777B | 475.949B | -45.172B | -9.49% |
| Q1 2019 Q2Q % growth | 449.834B | 447.597B | 2.237B | 0.50% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -126.87% | -537.2% | 3.62% | 4.94% |
| Revenue | 1.6% | -1.11% | 0.2% | 1.87% |